Emergence of acyclovir (Acy)-resistant herpes simplex virus (HSV) is a major concern in bone marrow transplant recipients. Phenotypic and genetic characterization of thymidine kinase (TK) was done for 7 Acy-susceptible and 11 Acy-resistant HSV-1 isolated from 11 patients. In total, 19 amino acid substitutions were detected that were not related to Acy resistance but to TK gene polymorphism, including 5 mutations that have not been previously reported. The Acy-resistant strain from 1 patient presented no TK gene mutation related to resistance. Five patients (45%) had isolates that harbored point mutations leading to amino acid substitutions that could be associated with Acy resistance. Of the 5 substitutions detected, 3 have not been previously reported (codons 51, 83, and 175). A nucleotide insertion or deletion was detected in resistant isolates from 5 patients (45%); these mutations are located in homopolymer repeats at codon 92 (1 subject) and at codon 146 (4 subjects).
Herpes simplex virus (HSV) infections are common after bone marrow transplantation and are associated with significant morbidity and mortality. These infections are efficiently prevented and treated with acyclovir (Acy), a nucleoside analogue that inhibits viral replication. To be active, Acy must be phosphorylated 3 times: the first phosphorylation is performed by the virus-encoded thymidine kinase (TK), and the last 2 phosphorylations are achieved by cellular thymidylate kinases. Acy triphosphate acts by competitive inhibition of viral DNA polymerase and is a DNA chain terminator.
Subsequent to the widespread use of Acy, several reports have described the emergence of Acy-resistant strains, mainly among immunocompromised patients, with a prevalence estimated at 5% [1, 2] . Resistance may be related to a mutation of either viral TK or viral DNA polymerase. Mutations in the viral gene encoding TK may lead either to a deficient TK or to a TK with an altered substrate specificity.
HSV-1 TK is a 376-amino acid (aa) protein that is encoded by a gene of 1128 bp. It exhibits an ATP binding site (aa 51-63) and a nucleoside binding site (aa 168-176), as proposed by Darby et al. [3] . Regions conserved among herpesviridae are also located at aa 50-66, 79-91, 162-178, 212-226, and 281-292 [4] . Certain TK mutations, possibly related to resistance, have been reported: mutations at aa 176 [3, 5, 6] and 336 [3, 6, 7] and frameshift mutations in a 7Gs homopolymer repeat located at codon 146 [6, [8] [9] [10] . Most of these genetic data were obtained from Acy-resistant strains isolated from AIDS patients.
Since 1985, our laboratory has systematically investigated HSV susceptibility to Acy. About 300 clinical isolates are tested each year, regardless of clinical origin. Acy-resistant strains have been detected in immunocompromised persons, mainly AIDS patients and transplant recipients. We have undertaken the genetic characterization of these resistant isolates in order to set up a database on TK mutations responsible for resistance to Acy. We present here the results of the characterization of the viral gene encoding TK for Acy-resistant HSV-1 isolated from bone marrow transplant recipients.
Materials and Methods
Patients. Acy-resistant HSV was isolated from 11 bone marrow transplant patients: 6 children and 5 adults. Children received systematic Acy prophylaxis orally (3 cases; regimen: 200 mg 4ϫ/ day) or intravenously (2 cases; regimen: 250 mg/m 2 for patient 1 or 500 mg/m 2 for patient 3, 3ϫ/day). Adults received a systematic intravenous Acy prophylaxis (regimen: 500 mg, 3ϫ/day). Patients were treated from the day after transplantation until the end of aplasia (3-4 weeks) or mucositis recovery. Antiviral prophylaxis with valacyclovir was then continued for 6 months (1 g/day). Virologic follow-up included analysis of systematic throat samples obtained from 1 week before transplantation until the end of apla- sia. Other biologic samples were taken in response to clinical features. Antiviral susceptibility studies. We evaluated the sensitivity of HSV isolates to Acy (GlaxoWellcome, Marly-le-Roi, France) and foscarnet (phosphonoformic acid; Astra, Nanterre, France). A neutral red dye-uptake assay was performed on Vero cells as described elsewhere [11] . Optical densities (at 540 nm, multichannel spectrophotometer, Titertek-Multiskan) were analyzed with the Biolise software program (Life Sciences International) to calculate the antiviral concentration causing a 50% inhibition of viral replication (IC 50 ). The mean IC 50 of the Acy-susceptible reference strain SC16 was mM. The cutoff value of IC 50 for resistance was 1.95 ‫ע‬ 0.50 established at 6.5 mM. For foscarnet, the mean IC 50 of the reference strain was mM, and the cutoff value for resistance was 245 ‫ע‬ 36 350 mM.
Genetic analysis: TK gene sequencing. The whole TK gene was amplified with 2 overlapping polymerase chain reactions (PCRs). The first began 38 nucleotides (nt) before the ATG initiation codon and ended at nt 581 by using the primers TK1 5 -GGGGA-TCCTCCCGCACCTCTTTGGC and TK3 3 -CGCAAGCACCG-GGAGTACCTAGGGG. The second region started at nt 526 and ended 19 nt after the stop codon with primers TK2 5 -GGG-GATCCGATACCTTATGGGCAGC and TK4 3 -TGTGCCTT-CCTCTGTTACCTAGGGG. PCR was done with the GC-rich PCR system (Roche Diagnostic Systems, Meylan, France) under the following conditions: 5 cycles at 94ЊC for 20 s, 55ЊC for 30 s, and 75ЊC for 5 min, followed by 30 cycles at 94ЊC for 20 s, 55ЊC for 30 s, and 75ЊC for 1 min, with a final extension step at 75ЊC for 5 min. The coding strand of the amplified DNA was sequenced with an automated sequencer (ESGS, Evry, France). Results were corroborated on DNA prepared from another PCR reaction. There were no discrepancies in sequences among duplicate PCRs. The TK gene sequence of each strain was compared with the Acysusceptible reference strain KOS.
Results
Isolates and patients. Clinical features of allogeneic transplantations (8 patients) are shown in table 1. Clinical data were not available for 3 patients (2 adults [patients 10 and 11] and 1 child [patient 6]), who received autologous transplantation. Among pediatric patients, HSV resistant to Acy was detected a mean of 1 month after transplantation, regardless of whether Acy was administered orally or intravenously. Among the adult patients, 2 had a resistant virus 6 months after transplantation; patient 7, who had a resistant strain 11 days after transplantation, had several mucitis episodes treated with Acy before transplantation.
When an Acy-resistant HSV was detected, the antiviral treatment was switched to either intravenous Acy (with an increasing regimen) or foscarnet. The mean time for healing was 17 days, except for patients 1 and 3, who presented with chronic infections over several months, and patient 9, who died soon after the emergence of the resistant HSV.
Phenotypic and genetic characterization of clinical strains. Of the 11 patients, 10 excreted strains resistant to Acy but susceptible to foscarnet. Patient 11 excreted viruses that were resistant to both Acy and foscarnet (11/2; table 1). We sequenced the TK gene from 11 Acy-resistant HSV clinical isolates plus susceptible strains isolated from the same patients prior to the emergence of resistant virus. Acy-susceptible iso- Most were detected in 2 or 3 isolates, except mutations at codons 85 and 192, which were detected only once, and codon 367, which was found mutated in the 7 Acy-susceptible isolates sequenced.
The resistant isolates from patients without previous Acysusceptible isolates also had many mutations that are probably not associated with resistance, because of the presence of other mutations that induce a frameshift (patients 5 and 9) or that have already been associated with the emergence of a resistant strain (patients 3 and 10, mutations at codons 175 and 105, respectively). These mutations are likely associated with TK gene polymorphism. They affect codons 17, 23, 36, 42, 77, 281, 364, and 374.
Mutations responsible for Acy resistance. Among the 11 resistant strains characterized in this study, 10 had 1 mutation that could account for resistance to Acy. The resistant isolate of patient 1 had no additional mutation in its TK gene, compared with the Acy-susceptible strain isolated earlier from the same patient. Single nt substitutions were detected in 5 isolates (patients 1, 3, 4, 6, and 10). Five other resistant strains had a single nt insertion (4 patients) or deletion (1 patient) that could result in a premature stop codon and the synthesis of a truncated protein. The nt insertion and deletion were located in a 5 or 7 Gs homopolymer repeat (at codons 92 or 146, respectively).
Discussion
The emergence of viruses resistant to Acy has often been reported and is becoming a major concern for bone marrow recipients. We identified Acy-resistant HSV-1 isolates in 11 patients. Ten excreted strains were resistant to Acy but susceptible to foscarnet, suggesting that mutations in the viral gene encoding TK are involved in the mechanism of resistance. One patient presented with virus resistant to Acy and foscarnet, and no additional modification of TK sequence was detected in this virus, compared with a sensitive isolate from the same patient, which suggests that this virus is a DNA polymerase mutant.
Our study focused on the characterization of the viral gene encoding TK of strains isolated in bone marrow transplant patients. The study of Acy-susceptible isolates revealed 11 aa substitutions unrelated to resistance. The substitutions were located throughout the gene but always outside TK active sites; moreover, all but 2 (codons 85 and 286) were outside TKconserved sites. The characterization of Acy-resistant virus isolated from patients without Acy-susceptible strains available revealed 8 other mutations that could be associated with TK gene polymorphism rather than with Acy resistance. These were located outside TK conserved sites and were associated with another mutation that could itself induce resistance (frameshift mutation or mutation previously described in Acy-resistant virus). Compared with results previously published [12, 13] , we report 5 new substitutions of aas that have no consequences on Acy susceptibility: substitutions of codons 17, 77, 85, 364, and 374. Amino acid substitutions that could be associated with the loss of TK activity have been detected in strains isolated from 5 patients. Two of these substitutions have been reported in Acy-resistant HSV: aa 104 and 105 [6, 14] .
One patient presented a virus harboring a substitution of glutamine at position 83. This aa of HSV-1 TK is located in a conserved site and is an analogue to glutamine at position 48 of varicella-zoster virus (VZV) TK. Mutation of this aa has been reported in Acy-resistant VZV isolates [15] . A modification of this glutamine may induce a major change in TK structure that leads to loss of enzyme activity and resistance to Acy. Two Acy-resistant clinical isolates presented with substitutions of either aa 51 or 175: Both are located in a conserved area of HSV TK, but their role in the emergence of Acy resistance needs to be assessed through additional investigations.
We detected insertion or deletion in about half of the resistant strains characterized in this study. These frameshift mutations are common among Acy-resistant HSV isolates [6] . The mutations identified here are located in homopolymer repeats of guanines or cytosines that are mutational hot spots. These mutations were found in repeats located at codon 92 (5 guanines) for 1 patient and at codon 146 (7 guanines) for 4 patients. To date, an nt insertion or deletion in this 7-guanine repeat has been reported in 11 resistant strains [6, 8, 9] .
Our work provides additional data on TK mutations associated with the emergence of Acy-resistant HSV. This study also demonstrates a large degree of polymorphism in the HSV viral gene encoding TK. This feature reinforces the relevance of regular virologic surveys, especially in severely immunocompromised patients. Indeed, the relation between the acquisition of resistance to Acy and the apparition of a mutation in the TK gene is easier to define if a sensitive strain previously isolated from the same patient is available.
According to the literature and to our results, TK gene polymorphism is unlikely to affect conserved sites of HSV TK. Moreover, aa substitutions that could be associated with resistance are located in TK-conserved sites. Therefore, the genetic detection of mutations associated with resistance should focus on active and conserved sites of HSV TK.
